MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -28.86% | -45.84% | -77.47% | -83.86% | 21.10% |
| Total Depreciation and Amortization | 3,904.00% | 15.66% | 23.25% | -93.67% | 10,821.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -114.98% | 7.82% | 7.95% | 34.27% | 244.17% |
| Change in Net Operating Assets | -147.09% | 255.65% | -87.08% | 55.69% | -761.00% |
| Cash from Operations | -91.79% | 9.38% | -86.58% | -21.10% | -33.44% |
| Capital Expenditure | -32.83% | -- | 100.00% | 25.58% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -351.92% | 166.57% | -206.87% | -124.41% | 167.18% |
| Cash from Investing | -352.79% | 166.42% | -204.62% | -124.65% | 167.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 65.06% | -- | -100.00% | 68.56% | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | 100.00% | 43.25% | -- |
| Cash from Financing | -17.70% | -- | -100.00% | 79.40% | -- |
| Foreign Exchange rate Adjustments | 230.24% | -1,825.44% | -136.34% | -28.13% | 1,194.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -694.03% | 128.42% | -1,690.41% | -94.53% | 172.43% |
